Boehringer Ingelheim cooperates with Aargau start-up

The Aargau start-up InterAx Biotech has developed a platform that helps to discover novel drug candidates. Now it is cooperating with the German pharma company Boehringer Ingelheim on the in-depth characterization of a specific drug candidate.

The three founders of InterAx Biotech Martin Ostermaier, Luca Zenone and Aurelien Rizk.
The three founders of InterAx Biotech Martin Ostermaier, Luca Zenone and Aurelien Rizk (from left to right). Image credit: Paul Scherrer Institute

InterAx Biotech and Boehringer Ingelheim are collaborating. According to a press release, the German pharma company will use the proprietary InterAx systems biology platform to characterize a drug candidate for an undisclosed target.

InterAx Biotech is a spin-off from the Swiss Federal Institute of Technology Zurich (ETH) and the Paul Scherrer Institute (PSI). The platform of the Villigen-based company is intended to speed up the discovery of novel drug candidates, with the focus on G protein-coupled receptors (GPCRs). These transmit the signals of active substances from the outside to the inside of the cell and trigger reactions in it.

InterAx Biotech has already won over several investors with its platform. At the beginning of the year the company secured 3 million Swiss francs in a financing round. The round was led by the US venture capital company Falcon III Ventures and​​​​​​

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program